3 completed. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
| Phase 2 | 1 | Completed 1 |
Follow aviptadil: new trials by email Literature Review of aviptadil trials Research Report on aviptadil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) Aviptadil, Aviptadil Placebo, Corticosteroid - Covid19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 471 | 2021-04-20 | 2025-10-09 |
| ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 Remdesivir, Remdesivir Placebo, Aviptadil - Covid19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 473 | 2021-04-20 | 2025-10-24 |
| Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure Aviptadil by intravenous infusion + standard of care, Normal Saline Infusion + standard of care - Critical COVID-19 With Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS) | Phase 2 / Phase 3 | Completed | APR Applied Pharma Research s.a. | 203 | 2020-05-15 | 2023-07-24 |
COVID-19 (3) · Coronavirus Infections (3) · Coronaviridae Infections (2) · Nidovirales Infections (2) · RNA Virus Infections (2) · Severe Acute Respiratory Syndrome (2) · Virus Diseases (2) · Acute Lung Injury (1) · Respiratory Distress Syndrome (1) · Respiratory Insufficiency (1)
National Institute of Allergy and Infectious Diseases (NIAID) (2) · APR Applied Pharma Research s.a. (1)
United States (3)
Prof. James Neaton (2) · Samuel Brown, MD (2) · Jonathan C Javitt, MD, MPH (1)